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Detection of Recurrence by 
18F-FDG PET in Patients with 
Endometrial Cancer Showing No Evidence of Disease
This study assessed the feasibility of F-18-fluorodeoxyglucose positron-emission 
tomography (
18F-FDG PET) in the post-therapy surveillance for patients with endometrial 
cancer showing no evidence of disease (NED). From April 1997 to June 2007, 127 patients 
with endometrial cancer showing NED were performed 
18F-FDG PET scan. The feasibility of 
18F-FDG PET for the early detection of recurrence in patients with endometrial cancer was 
evaluated retrospectively. Of the 127 patients, 32 patients showed positive lesions on 
18F-FDG PET scan. Nineteen (19/127 cases, 15%) of them were confirmed to have a 
recurrence clinically or histologically. The sensitivity, specificity and positive and negative 
predictive value of 
18F-FDG PET for detecting recurrences in patients with endometrial 
cancer were 100%, 88%, 59% and 100%, respectively. In conclusion, 
18F-FDG PET may be a 
useful method for the post-therapy surveillance in patients with endometrial cancer.
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INTRODUCTION
Endometrial cancer is one of the most common malignant tu-
mors of women, and has a favorable prognosis if it is detected 
in the early stage (1). However, about one-fourth of patients with 
early endometrial cancer will eventually develop recurrences (2). 
The patients with a recurrence can be salvaged by radiotherapy 
or systemic chemotherapy; however, the prognosis of patients 
with recurrent endometrial cancer is known to be poor (2, 3).
  The early detection of recurrence provides patients with an 
opportunity to receive more sophisticated treatment, which 
could impact on patient survival for many human cancers (4). 
However, there are few methods to detect early recurrences for 
patients with endometrial cancer at a point that improves sur-
vival by salvage therapy. 
  The conventional follow-up methods after the treatment of 
endometrial cancer include physical examination, Papanico-
laou (PAP) smear, tumor markers such as CA-125 and imaging 
studies such as computed tomography (CT) or magnetic reso-
nance imaging (MRI) (5). However, the early detection of recur-
rences by conventional follow-up methods is known to be un-
satisfactory. It has recently been reported that the detection rates 
in asymptomatic patients with recurrence of endometrial can-
cer were as low as 5% to 33% with physical examination, 0% to 
4% with PAP smear, 0% to 14% with chest radiography, 4% to 13% 
with abdominal ultrasound, 5% to 21% with abdominal/pelvis 
CT and 15% with serum CA-125 level, which implicates the need 
for more sophisticated post-therapy surveillance methods (5).
  F-18-fluorodeoxyglucose positron-emission tomography (
18F-
FDG PET) is an up-to-date imaging technique that utilizes 
18F-
FDG, which is preferentially trapped in tumor cells and so it re-
veals functional images of high glucose metabolism. The func-
tional image of 
18F-FDG PET can differentiate recurrences from 
the lesions distorted by the fibrosis that happens after surgery 
or radiotherapy (6). 
18F-FDG PET also has high resolution pow-
er to detect lesions less than 1 cm, which are frequently missed 
by conventional imaging methods (7, 8).
  In several human cancers, 
18F-FDG PET is widely used for de-
tecting early recurrences and it is known to be more accurate 
than CT or MRI (9, 10). We previously reported that 11% of the 
patients (28/249 patients) with cervical cancer showing no evi-
dence of disease (NED) were identified to have recurrent lesions 
on 
18F-FDG PET. The sensitivity and specificity of 
18F-FDG PET 
for detecting recurrence in patients with cervical cancer show-
ing NED were 90% and 76%, respectively (11). For ovarian can-
cers, the sensitivity of 
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es was reported to be almost 100% (12). However, there are cur-
rently few studies on the feasibility of 
18F-FDG PET as an effec-
tive tool of post-therapy surveillance in patients with endome-
trial cancer.
  According to the recent studies, the sensitivity, specificity and 
positive predictive value (PPV) and negative predictive value 
(NPV) of 
18F-FDG PET for post-therapy surveillance in patients 
with endometrial cancer were reported to be 93-96%, 78-100%, 
89-100% and 91-92%, respectively (13, 14). However, the reports 
were limited by the small number of patients as there were only 
around 30 cases of patients with endometrial cancer at best (13-
15). Therefore, the feasibility of 
18F-FDG PET for the post-thera-
py surveillance in patients with endometrial cancer remains to 
be clarified in larger series of patients. 
  In this study, we investigated the feasibility of 
18F-FDG PET 
for the post-therapy surveillance in 127 patients with endome-
trial cancer who showed NED after their initial treatment.
 
MATERIALS AND METHODS
Patients
One hundred twenty-seven patients with endometrial cancer 
showing NED after their initial treatment between April 1997 
and June 2007 at Korea Cancer Center Hospital were enrolled 
in this study. The clinical characteristics such as age, stage and 
histologic grade were collected from the medical records, and 
were analyzed retrospectively. The institutional review board 
approved this study (K-0909-027-021).
  All the patients were pathologically proven to have endome-
trial cancer, and were performed comprehensive surgical stag-
ing procedures including total abdominal hysterectomy, bilat-
eral salpingo-oophorectomy, pelvic and para-aortic lymphade-
nectomy and intraperitoneal washing cytology. Adjuvant radio-
therapy was applied when the postoperative pathological ex-
amination revealed risk factors for recurrence. 
  After treatment, the patients were observed every 3 months 
during the first 2 yr and every 6 months thereafter for 5 yr with 
physical examinations, PAP smears, serum CA-125 levels and 
annual imaging studies such as chest radiography, CT or MRI. 
  We defined NED as all normal follow-up tests, including the 
physical examinations, PAP smears, chest radiography, serum 
CA-125 levels and imaging studies. 
18F-FDG PET scan
18F-FDG PET scan was performed for all patients who showed 
NED in conventional post-therapy surveillance. Conventional 
post-therapy surveillance included physical examination, PAP 
smears, serum CA-125 levels and annual imaging studies. 
18F-
FDG PET scan was performed within 3 months after conven-
tional surveillance. 
18F-FDG PET was performed on an ECAT 
HR+ (Siemens, Knoxville, TN, USA) or an Advance HR+ Scan-
ner (General Electric, Waukesha, WI, USA). Their intrinsic spa-
tial resolutions on the axial plane were 6 mm and 4.6 mm, re-
spectively, and the thickness of the slice was 4.25 mm. 
  The patients fasted for at least 6 hours before 
18F-FDG injec-
tion to reduce the serum glucose and insulin levels to near bas-
al concentrations. In order to decrease the misinterpretation 
caused by the accumulation of 
18F-FDG in the bladder and ure-
ter, we inserted a Foley catheter and injected furosemide 40 mg 
intravenously 60 min before scanning. 
  After the intravenous injection of 370-555 Mbq of 
18F-FDG, the 
transmission images were obtained for 3 min with using Ge-68, 
and segmented attenuated correction was applied. The attenu-
ated corrected images were reconstructed using a Hanning fil-
ter (cut-off 8.0 mm), and the ordered subset expectation maxi-
mization method was adopted as the reconstruction algorithm 
in both scanners.
  The 
18F-FDG PET images were interpreted by consensus of 
two nuclear medicine doctors who were kept “blind” to the pa-
tients’ clinical and radiological information. Any suspicious hot 
uptakes, except physiologic uptakes such as bowel activity with 
linear nature or mediastinal lymph node activity with calcifica-
tion, were interpreted as positive.
Diagnosis of recurrence
The recurrence was diagnosed histologically as much as it is pos-
sible. In any suspicious hot uptake on 
18F-FDG PET, percutane-
ous fine needle aspiration cytology or biopsy was performed to 
confirm the recurrence. 
  For the deep lymph nodes, where cytology or biopsy was not 
applicable, 1) the lesions with a short axis >1 cm on imaging 
study such as CT or MRI were interpreted as metastasis, and 2) 
the lesions with a short axis <1 cm were followed-up by CT or 
MRI after 3 months. More than 20% change of size of the tumor 
on follow-up CT was determined to have a recurrence. If there 
was no change of size on the follow-up imaging study, then the 
patients were recommended for follow-up every 3 months for a 
year. 
  Other hot uptake lesions on 
18F-FDG PET other than the lymph 
node were evaluated by biopsy, as much as it is possible. Any 
lesion for which biopsy was not applicable was examined by fol-
low-up CT or MRI within 3 months and close observation for a 
year was recommended. 
  Two expert radiologists reviewed the CT or MRI image and 
came to a consensus without any 
18F-FDG PET data and clinical 
information.
 
RESULTS
The median age of the patients with endometrial cancer who 
showed NED was 52 yr (range, 27-71). The proportion of the 
FIGO stage was 79% in stage I, 4% in stage II, 15% in stage III and Ryu S-Y, et al.  •  Detection of Recurrence by PET in Patients with Endometrial Cancer
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2% in stage IV. The histologic type was mostly the endometrioid 
type (86%) and the histologic grade was I or II in 86% of the cas-
es. The median interval from the initial diagnosis of endometri-
al cancer to 
18F-FDG PET was 30 months (Table 1).
  Of the 127 patients, 32 patients showed positive lesions on 
18F-FDG PET. Among them, 19 patients were confirmed to have 
recurrence clinically and/or histologically (19/127 patients, 15%) 
(Fig. 1). Seven patients (37%) had only local recurrences, a pa-
tient (5%) had only distant recurrence, and 11 patients (58%) 
had a mix of distant and local recurrences (Table 2). Most of the 
recurrences were detected within 12 months after the initial di-
agnosis of endometrial cancer (11/19 patients, 58%) (Fig. 2).
  The sensitivity, specificity, PPV and NPV of 
18F-FDG PET for 
detecting the recurrence in patients with endometrial cancer 
showing NED were 100%, 88%, 59%, and 100%, respectively 
(Table 3). The site-specific sensitivity and specificity of 
18F-FDG 
PET were generally high regardless of the site of recurrences, 
however, the false positive rate was high for the vaginal stump 
(3/3 cases), spine (2/2 cases), and inguinal lymph node (1/1 cas-
es) (Table 4). There was a site-specific false negative lesion in 
the lung parenchyma, which was not detected by 
18F-FDG PET, 
but was detected by additional chest CT scan. 
 
Table 1. Clinical characteristics 
Clinical characteristics Values (n=127)
Median age (range) 52 (27–71 yr)
Stage (%)
   I
   II
   III
   IV
101 (79)
  5 (4)
  19 (15)
  2 (2)
Histologic type (%)
   Endometrioid
   Adenosquamous
   Others*
109 (86)
   5(4)
  13 (10)
Grade (%)
   1
   2
   3
  52 (41)
  57 (45)
  18 (14)
Interval from initial diagnosis to 
18F-FDG PET, 
   median (range), month 
30 (6-279)
*Six papillary serous, 5 clear cell, 2 undifferentiated. 
Table 2. Clinical characteristics of the patients with recurrence
Clinical characteristics Values (n=19)
Stage (%)
   I
   II
   III
   IV
  9 (47)
0 (0)
  9 (47)
1 (5)
Histologic type (%)
   Endometrioid
   Adenosquamous
   Others
16 (84)
  2 (11)
1 (5)
Grade (%)
   1
   2
   3
  4 (21)
  9 (47)
  6 (32)
Recurrence pattern (%)
   Local
   Distant+local
   Distant
  7 (37)
11 (58)
1 (5)
Fig. 2. Interval from the initial diagnosis to 
18F-FDG PET for the patients with 
endometrial cancer who had recurrent disease. 
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Fig. 1. A case where 
18F-FDG PET detected a recurrent lesion in a patient showing 
no evidence of disease at conventional studies. CT scan detected no lesion and the 
level of tumor marker was within normal range. However, PET scan detected a 
recurrent lesion (arrow) at small bowel mesentery. Retrospective review of CT scan 
revealed a lesion smaller than 1 cm (arrow) at small bowel mesentery. Bowel 
obstruction symptoms developed three weeks later and surgical exploration revealed 
a recurrent lesion at small bowel mesentery.Ryu S-Y, et al.  •  Detection of Recurrence by PET in Patients with Endometrial Cancer
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DISCUSSION
This study showed that 
18F-FDG PET could effectively detect ear-
ly recurrences in patients with endometrial cancer showing NED 
after primary treatment. Nineteen patients who were confirmed 
to have recurrence in this study did not have any sign of recur-
rence by conventional follow-up methods including physical 
examination, PAP smear, serum CA-125 level and imaging study 
such as CT or MRI. Thus, the 19 patients (15%, 19/127 patients) 
who were identified to have recurrence were detected solely by 
18F-FDG PET. 
  The feasibility of 
18F-FDG PET for detecting early recurrence 
in patients with endometrial cancer was already suggested by 
several studies that had the limitation of a small number of cas-
es. A study on 
18F-FDG PET for the post-therapy surveillance in 
34 patients with endometrial cancer showed that early recur-
rence was detected by 
18F-FDG PET in 12% of patients who were 
not suspected to have recurrence at the control visits (7). How-
ever, because the population of the previous studies is small and 
limited, the role of 
18F-FDG PET as a post-therapy surveillance 
method has been remained unclear. 
  Our study confirmed that 15% of patients with endometrial 
cancer who showed NED by conventional follow-up methods 
had a recurrence, showing that 
18F-FDG PET was a useful post-
therapy surveillance method in patients with endometrial can-
cer. The number of enrolled patients in this study is the largest 
series up-to-date, and it well represents the general characteris-
tics of patients with endometrial cancer (Table 1). 
  The higher detection rate of 
18F-FDG PET over conventional 
imaging methods such as CT or MRI can be explained in sever-
al ways. First, 
18F-FDG PET detects the metabolic change that 
precedes the anatomical change (8). This characteristic of 
18F-
FDG PET is particularly useful for lesions where the anatomical 
structure is deformed by fibrosis due to previous surgery or ra-
diotherapy (6, 9). Second, 
18F-FDG PET is convenient for obtain-
ing a whole-body image at once. It is known that distant metas-
tases frequently occur in patients with endometrial cancers; 
however, the conventional follow-up methods are usually lim-
ited to the abdomen and pelvis (16). This suggests that 
18F-FDG 
PET can be useful as a post-therapy surveillance tool in patients 
with endometrial cancer because 
18F-FDG PET can obtain a 
whole-body image at once. 
  Most recurrences in patients with endometrial cancer are 
known to develop within two years (2). In this study, 58% of the 
recurrences were detected within 12 months, suggesting that 
18F-FDG PET could detect recurrences earlier than the conven-
tional methods. The early detection of recurrence is important 
because it provides an earlier opportunity for salvage treatment, 
which might improves the prognosis (17). It was recently report-
ed that the early detection of recurrence by 
18F-FDG PET signifi-
cantly altered the treatment plan in patients with endometrial 
cancer, which supports the importance of early detection of re-
currence (7). In this study, even though most of the recurrence 
was detected at 6-12 months after treatment, the optimal time 
of 
18F-FDG PET should be investigated by prospective studies.
  Although 
18F-FDG PET showed a high sensitivity and speci-
ficity for detecting recurrent lesions, a high false positivity was 
reported as well (7, 11, 18). In this study, the high false positivity 
of 
18F-FDG PET was observed in the vaginal stump, spine and 
inguinal lymph nodes, where the physiologic uptake by the blad-
der, ureter and intestine is common. The relative low PPV of 
18F-
FDG PET in this study also arose from the high false positivity 
in these areas. Therefore, hot uptake lesions on 
18F-FDG PET in 
the vaginal stump, spine and inguinal lymph nodes should be 
interpreted more carefully to exclude the possibility of false pos-
itivity. However, we thought that the false positive lesions on 
PET could be correctly interpreted as physiologic uptake if the 
PET/CT had been performed. Considering the PET/CT is gain-
ing popularity in Korea, further studies on the role of PET/CT in 
post-therapy surveillance of endometrial cancer is necessary.
  There was a pulmonary metastasis smaller than 1 cm that was 
not detected by 
18F-FDG PET, but it was detected by additional 
chest CT scan. The false negativity of 
18F-FDG PET for lung lesion 
was also reported in other studies, and this can be explained by 
Table 3. Detection of recurrence with 
18F-FDG PET in endometrial cancer patients 
showing NED (n=127)
18F-FDG PET No. of patients (%)
18F-FDG PET (-) 95 (75)
   True negative
   False negative
95 (75)
0 (0)
18F-FDG PET (+) 32 (25)
   True positive
   False positive
19 (15)
13 (10)
Table 4. Accuracy of 
18F-FDG PET according to the site of recurrences 
Site of recurrences
18F-FDG PET (+)
18F-FDG PET (-) Sn  
(%)
Sp  
(%) TP FP TN FN
Local recurrences 16 11 100 0 100   90
   Vaginal stump
   Pelvis
   Paraaortic LN
   Inguinal LN
  0
10
  6
  0
  3
  7
  0
  1
124
110
121
126
0
0
0
0
-
100
100
-
  98
  94
100
  99
Distant recurrences 19   3 104 1   95   97
   Pulmonary hilar LN
   Scalene LN
   Mediastinal LN
   Lung
   Liver
   Spine
   Small bowel
  2
  3
  1
  7
  5
  0
  1
  0
  1
  0
  0
  0
  2
  0
125
123
126
119
122
125
126
0
0
0
1
0
0
0
100
100
100
  88
100
-
100
100
  99
100
100
100
  98
100
Pulmonary hilar LN: the proximal lobar nodes, distal to the mediastinal pleural ref–
lection and the nodes adjacent to the bronchus intermedius on the right; Mediastinal 
LN, from highest mediastinal lymph node to pulmonary ligament nodes except hilar 
lymph node.
LN, lymph node; TP, true positive; FP, false positive; TN, true negative; FN, false nega–
tive; Sn, sensitivity; Sp, specificity. Ryu S-Y, et al.  •  Detection of Recurrence by PET in Patients with Endometrial Cancer
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the small size of the lesion, which was below the resolution pow-
er of 
18F-FDG PET, or the respiratory movement of the lung pa-
renchyma, which may obscure the accuracy of 
18F-FDG PET (7).
  In conclusion, our study showed that 
18F-FDG PET could de-
tect recurrences in 15% of the patients with endometrial cancer 
who showed NED by the conventional follow-up methods. 
18F-
FDG PET may be a useful method for post-therapy surveillance 
and provide the opportunity for a more sophisticated treatment 
in patients with endometrial cancer. 
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